This study is for men with prostate cancer that has spread to a few (oligometastatic) areas, like bones or soft tissue, at the time of diagnosis. Researchers want to see if adding stereotactic ablative radiation therapy (SABR) to metastatic lesions improves outcomes compared to standard treatment alone. Standard treatment includes systemic therapy (medicine given throughout the body) and radiation to the prostate. The main goal is to see how many men are free from their cancer getting worse after two years. You might be able to join if you are a man, 18 or older, and have 1 to 3 new metastatic tumors (up to 5 on advanced scans) that appeared within the last 6 months. The study status is currently unclear.

Study design

This interventional study plans to enroll 122 men. It compares two treatment approaches: standard care (systemic therapy + prostate radiation) versus standard care plus SABR to metastatic lesions.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long participants are free from cancer progression at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.